secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0000320017-23-000021
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics eliminates President & CBO role, terminates David Slack effective May 1, 2023
--------------------------------------------------------------------------------

- Position of President and Chief Business Officer eliminated; David Slack terminated immediately.
- Slack resigned from Board of Directors per employment agreement.
- Severance: $478,400 over 12 months; bonus of $239,200 (50% of base salary) paid over same period.
- Additional lump sum of $24,134 for earned pay, PTO, and expenses; COBRA assistance provided.
- Vested option exercise period extended to three years post-termination or remaining term, whichever shorter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000021/0000320017-23-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000021/clbs-20230501.htm
  HTML page:      https://secwatch.observer/filing/0000320017-23-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer